Zentalis published survival data for Zentalis Pharmaceuticals stock

Published on 10/21/2026 at 06:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zentalis reported 15.8 months of median survival on October 18, 2026. Zentalis Pharmaceuticals stock has a presentation on October 23, 2026.

Survival data and trial milestones

Zentalis published 15.8 months of median overall survival data on October 18, 2026.
The DENALI Part 1b study enrolled 102 patients with platinum-resistant ovarian cancer.
A rapid oral presentation on October 23, 2026, will detail the azenosertib results.

ZNTL, US98943L1070, Illustration mit AI erstellt.

Zentalis Pharmaceuticals (US98943L1070) published median overall survival of 15.8 months for a biomarker-defined patient group on October 18, 2026. Zentalis Pharmaceuticals said the figure came from an interim analysis of the DENALI Part 1b study of investigational azenosertib.

Biomarker separates survival outcomes

The survival result differed sharply by Cyclin E1 status. Cyclin E1-positive patients recorded median overall survival of 15.8 months, compared with 7.5 months for Cyclin E1-negative patients, according to the October 18 release.

The positive subgroup included 48 patients, while the negative subgroup included 46. The full study enrolled 102 people with platinum-resistant ovarian cancer after one to five prior treatment lines, making the biomarker distinction central to the development strategy.

What does the survival result mean for the program?

The data support further testing rather than an approval decision. Zentalis is advancing DENALI Part 2 and the ASPENOVA Phase 3 trial, while the company describes Cyclin E1 as a predictive biomarker for azenosertib response.

For context, Investing.com reported on October 19, 2026, that H.C. Wainwright reiterated a Buy rating and a USD 10.00 price target. MarketBeat reported on October 15, 2026, that Jefferies upgraded the stock from Hold to Strong Buy.

Three recent milestones

On October 1, 2026, Zentalis granted options covering 62,000 shares to three new employees, according to its investor-relations release. On October 15, 2026, Jefferies upgraded the stock from Hold to Strong Buy, as reported by MarketBeat. On October 18, 2026, Zentalis published the 15.8-month median survival result.

Next clinical date

The next substantiated event is a rapid oral presentation of the DENALI Part 1b data at ESMO Congress on October 23, 2026, according to Zentalis. The presentation will cover the overall survival analysis in platinum-resistant ovarian cancer.

Nasdaq valuation context

Zentalis was last at USD 2.39 on Nasdaq on October 20, 2026, at 4:00 p.m. ET. Its market capitalization was USD 170.1 million, and its 52-week range was USD 1.21 to USD 6.95.